Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system

[1]  Rakesh Kumar,et al.  Estrogen Receptor Expression and Function in Long-Term Estrogen-Deprived Human Breast Cancer Cells* * This work was supported by Grants NIH-RO-1-65622-04 (to R.J.S.), HD-25719 (to M.A.S.), GM-55985 and CA-44579 (to T.P.B.), and CA-65746 (to R.K.). , 1998, Endocrinology.

[2]  N. Hay,et al.  Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. , 1998, Molecular endocrinology.

[3]  G. Wilding,et al.  Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[4]  J C Reed,et al.  BAG-1L Protein Enhances Androgen Receptor Function* , 1998, The Journal of Biological Chemistry.

[5]  T. Ikonen,et al.  Interaction between the Amino- and Carboxyl-terminal Regions of the Rat Androgen Receptor Modulates Transcriptional Activity and Is Influenced by Nuclear Receptor Coactivators* , 1997, The Journal of Biological Chemistry.

[6]  H. Klocker,et al.  Synergistic activation of androgen receptor by androgen and luteinizing hormone‐releasing hormone in prostatic carcinoma cells , 1997, The Prostate.

[7]  B. Foster,et al.  Analysis of growth factor and receptor mRNA levels during development of the rat seminal vesicle and prostate. , 1997, Development.

[8]  W. Rosner,et al.  Estradiol Activates the Prostate Androgen Receptor and Prostate-specific Antigen Secretion through the Intermediacy of Sex Hormone-binding Globulin* , 1997, The Journal of Biological Chemistry.

[9]  J Isola,et al.  Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. , 1997, Cancer research.

[10]  L. Chung,et al.  Androgen-repressed phenotype in human prostate cancer. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[11]  R. Hiipakka,et al.  Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[12]  C. Gupta,et al.  Activation of androgen receptor in epidermal growth factor modulation of fetal mouse sexual differentiation , 1996, Molecular and Cellular Endocrinology.

[13]  L. Nazareth,et al.  Activation of the Human Androgen Receptor through a Protein Kinase A Signaling Pathway* , 1996, The Journal of Biological Chemistry.

[14]  P. Chambon,et al.  TIF2, a 160 kDa transcriptional mediator for the ligand‐dependent activation function AF‐2 of nuclear receptors. , 1996, The EMBO journal.

[15]  P. Carroll,et al.  Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. , 1996, Cancer research.

[16]  S. Yeh,et al.  Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[17]  H. Klocker,et al.  Inhibitory effects of the nucleoside analogue gemcitabine on prostatic carcinoma cells , 1996, The Prostate.

[18]  H. Klocker,et al.  Androgen receptor status of lymph node metastases from prostate cancer , 1996, The Prostate.

[19]  H. Klocker,et al.  Distant metastases from prostatic carcinoma express androgen receptor protein. , 1995, Cancer research.

[20]  G. Bubley,et al.  Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. , 1995, The New England journal of medicine.

[21]  Jorma Isola,et al.  In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.

[22]  G. Prins,et al.  Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. , 1995, Endocrinology.

[23]  H. Klocker,et al.  Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. , 1995, European urology.

[24]  J Piper,et al.  Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors , 1994, Genes, chromosomes & cancer.

[25]  N. Hay,et al.  Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. , 1994, Cancer research.

[26]  H. Klocker,et al.  Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. , 1993, Molecular endocrinology.

[27]  A. Levine,et al.  Enhanced androgen sensitivity in serum-free medium of a subline of the LNCaP human prostate cancer cell line , 1993, Steroids.

[28]  T. H. van der Kwast,et al.  Hormone-induced dissociation of the androgen receptor-heat-shock protein complex: use of a new monoclonal antibody to distinguish transformed from nontransformed receptors. , 1992, Biochemistry.

[29]  T. H. van der Kwast,et al.  Androgen receptors in endocrine‐therapy‐resistant human prostate cancer , 1991, International journal of cancer.

[30]  G. Jenster,et al.  A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. , 1990, Biochemical and biophysical research communications.

[31]  A. Schuurmans,et al.  Regulation of growth and epidermal growth factor receptor levels of LNCaP prostate tumor cells by different steroids , 1988, International journal of cancer.

[32]  J. Horoszewicz,et al.  A high-resolution study of chromosome changes in a human prostatic carcinoma cell line (LNCaP). , 1984, Cancer genetics and cytogenetics.

[33]  G. Murphy,et al.  LNCaP model of human prostatic carcinoma. , 1983, Cancer research.

[34]  D C Ward,et al.  Enzymatic synthesis of biotin-labeled polynucleotides: novel nucleic acid affinity probes. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[35]  J. Lechner,et al.  Establishment and characterization of a human prostatic carcinoma cell line (PC-3). , 1979, Investigative urology.

[36]  D. Paulson,et al.  Isolation of a human prostate carcinoma cell line (DU 145) , 1978, International journal of cancer.

[37]  H. Scher,et al.  The antiandrogen withdrawal syndrome in relapsed prostate cancer. , 1997, European urology.

[38]  T. Visakorpi,et al.  Genetic changes associated with the acquisition of androgen-independent growth, tumorigenicity and metastatic potential in a prostate cancer model. , 1997, British Journal of Cancer.

[39]  H. Klocker,et al.  DNA sequence of the androgen receptor in prostatic tumor cell lines and tissue specimens assessed by means of the polymerase chain reaction , 1993, The Prostate.

[40]  C. Wilson,et al.  Androgen Receptor Gene Expression in Human Prostate Carcinoma Cell Lines1 , 1990 .

[41]  M. Chen,et al.  Aberrant response in vitro of hormone‐responsive prostate cancer cells to antiandrogens , 1989, The Prostate.

[42]  J. Romijn,et al.  Application of the MTT assay to human prostate cancer cell lines in vitro: Establishment of test conditions and assessment of hormone‐stimulated growth and drug‐induced cytostatic and cytotoxic effects , 1988, The Prostate.